Table 5. . Updates in neoadjuvant therapy for pancreaticobiliary cancer.
Study | Trial | Cancer type | Eligibility | Phase | Number of patients (n) | Timing | Intervention | Outcome | Ref. |
---|---|---|---|---|---|---|---|---|---|
Primrose et al. | BILCAP | Cholangiocarcinoma or gallbladder cancer | Macroscopically complete resection (R0 and R1) | III | 447 | Adjuvant | Capecitabine vs observation | Median OS 51.1 vs 36.5 mo (p = 0.097) | [62] |
Edeline et al. | UNICANCER | Biliary tract | Complete resection (R0 and R1) | III | 196 | Adjuvant | GEMOX vs observation | Median RFS 30.4 vs 22.0 mo (p = 0.31) | [66] |
Neoptolemos et al. | ESPAC-4 | Pancreatic | Resected adenocarcinoma of the pancreas (R0 or R1) | III | 730 | Adjuvant | GEMCAP vs GEM | Median OS 28.0 vs 25.5 mo (p = 0.032) | [75] |
mo: Month; OS: Overall survival; RFS: Relapse-free survival.